Vascular Pharmaceuticals, Inc.

Vascular Pharmaceuticals, Inc. is engaged in developing innovative therapies for diabetic nephropathy, a serious kidney complication linked to diabetes, with their lead product currently advancing through clinical trials. Founded in 2005 and headquartered in Burlington, US, Vascular Pharmaceuticals, Inc. specializes in treatments for diabetic nephropathy.

The founder, David Clemmons, has a background in drug development, and the company has raised a total of USD 9 mn through 2 funding deals, with the latest being a Series A round led by Lumira Ventures in February 2015, which was aimed at supporting the development of their lead product, VPI-2960B. The current CEO is Richard Shea. Vascular Pharmaceuticals focuses on developing innovative treatments for diabetic nephropathy, a serious kidney condition associated with Type 1 and Type 2 diabetes. Their lead product, VPI-2960B, is currently in Phase 2 clinical trials and aims to halt or reverse the progression of this disease, which currently has no cure.

The company targets individuals suffering from diabetes, offering a potential breakthrough in treatment options that could improve patient outcomes and enhance quality of life. Vascular Pharmaceuticals plans to market its products primarily in North America and Europe, where the prevalence of diabetes and its complications is significant. By addressing the unmet medical needs in these regions, the company seeks to serve a broad client base comprising healthcare providers, patients, and potentially, pharmaceutical partners. Vascular Pharmaceuticals operates on a model that includes partnerships and B2B transactions with healthcare providers and research institutions engaged in diabetes treatment.

The revenue structure involves agreements for clinical trial participation and collaboration with investors or pharmaceutical companies interested in the commercialization of VPI-2960B. Revenue is generated from contractual arrangements associated with its development and expected market introduction upon successful trials, enabling Vascular Pharmaceuticals to fund ongoing research while positioning itself for future sales targeting healthcare systems and direct consumers. The company has a strategic focus on advancing VPI-2960B through clinical trials, aiming for market introduction post successful outcomes. With the recent Series A funding round closing on February 9, 2015, which raised USD 9 mn, Vascular Pharmaceuticals plans to utilize these funds to accelerate the development of its lead product and explore opportunities for expansion into North American and European markets by 2025.

The funding will support ongoing research initiatives and potential collaborations with pharmaceutical partners to enhance their market presence.